靶向癌症和病毒治疗的创新蛋白质降解物

IF 3.5 3区医学 Q2 CHEMISTRY, MEDICINAL

ACS Medicinal Chemistry Letters Pub Date : 2025-01-29 DOI:10.1021/acsmedchemlett.5c0003010.1021/acsmedchemlett.5c00030

Robert B. Kargbo*,

{"title":"靶向癌症和病毒治疗的创新蛋白质降解物","authors":"Robert B. Kargbo*, ","doi":"10.1021/acsmedchemlett.5c0003010.1021/acsmedchemlett.5c00030","DOIUrl":null,"url":null,"abstract":"<p >The development of targeted protein degraders offers novel strategies for treating cancer and chronic viral infections. This Patent Highlight integrates bifunctional degraders, leveraging autophagy via p62, and substituted oxazolone compounds targeting IKZF1–4 transcription factors. These compounds demonstrate exceptional efficacy in degrading pathogenic proteins, reprogramming immune responses, and facilitating tumor immunity. This dual approach underscores the potential of cellular degradation systems in precision medicine.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 2","pages":"222–223 222–223"},"PeriodicalIF":3.5000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Innovative Protein Degraders for Targeted Cancer and Viral Therapy\",\"authors\":\"Robert B. Kargbo*, \",\"doi\":\"10.1021/acsmedchemlett.5c0003010.1021/acsmedchemlett.5c00030\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >The development of targeted protein degraders offers novel strategies for treating cancer and chronic viral infections. This Patent Highlight integrates bifunctional degraders, leveraging autophagy via p62, and substituted oxazolone compounds targeting IKZF1–4 transcription factors. These compounds demonstrate exceptional efficacy in degrading pathogenic proteins, reprogramming immune responses, and facilitating tumor immunity. This dual approach underscores the potential of cellular degradation systems in precision medicine.</p>\",\"PeriodicalId\":20,\"journal\":{\"name\":\"ACS Medicinal Chemistry Letters\",\"volume\":\"16 2\",\"pages\":\"222–223 222–223\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-01-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Medicinal Chemistry Letters\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00030\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Medicinal Chemistry Letters","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00030","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

摘要

靶向蛋白降解物的发展为治疗癌症和慢性病毒感染提供了新的策略。该专利重点集成了双功能降解剂，利用p62自噬，以及靶向IKZF1-4转录因子的取代恶唑酮化合物。这些化合物在降解致病蛋白、重编程免疫反应和促进肿瘤免疫方面表现出卓越的功效。这种双重方法强调了细胞降解系统在精准医学中的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Innovative Protein Degraders for Targeted Cancer and Viral Therapy

The development of targeted protein degraders offers novel strategies for treating cancer and chronic viral infections. This Patent Highlight integrates bifunctional degraders, leveraging autophagy via p62, and substituted oxazolone compounds targeting IKZF1–4 transcription factors. These compounds demonstrate exceptional efficacy in degrading pathogenic proteins, reprogramming immune responses, and facilitating tumor immunity. This dual approach underscores the potential of cellular degradation systems in precision medicine.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

ACS Medicinal Chemistry Letters CHEMISTRY, MEDICINAL-

CiteScore

7.30

自引率

2.40%

发文量

328

审稿时长

1 months

期刊介绍： ACS Medicinal Chemistry Letters is interested in receiving manuscripts that discuss various aspects of medicinal chemistry. The journal will publish studies that pertain to a broad range of subject matter, including compound design and optimization, biological evaluation, drug delivery, imaging agents, and pharmacology of both small and large bioactive molecules. Specific areas include but are not limited to: Identification, synthesis, and optimization of lead biologically active molecules and drugs (small molecules and biologics) Biological characterization of new molecular entities in the context of drug discovery Computational, cheminformatics, and structural studies for the identification or SAR analysis of bioactive molecules, ligands and their targets, etc. Novel and improved methodologies, including radiation biochemistry, with broad application to medicinal chemistry Discovery technologies for biologically active molecules from both synthetic and natural (plant and other) sources Pharmacokinetic/pharmacodynamic studies that address mechanisms underlying drug disposition and response Pharmacogenetic and pharmacogenomic studies used to enhance drug design and the translation of medicinal chemistry into the clinic Mechanistic drug metabolism and regulation of metabolic enzyme gene expression Chemistry patents relevant to the medicinal chemistry field.